You have little to no response to AAV the first time your body sees it. If you used the same vector twice you would want to bump up immunosuppression. I believe there will be many new ways to deliver genes in the future as well.

We have a battery of tests planned at regular intervals including DNA methylation analysis, gene expression profile changes, telomere length (both TAT and QTRAP measured) and various other metrics that will highlight positive changes to aging biomarkers.

Epigenetics is very important. We are keeping a close eye on iPS cells and other genetic methods of reprogramming the epigenome.

Liz Parrish Quotes